Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD20 monoclonal antibody B001

A recombinant humanized monoclonal antibody directed against human CD20 with potential antineoplastic activity. Upon intravenous administration, anti-CD20 monoclonal antibody B001 specifically binds to CD20 on the surfaces of B cells. Although the exact mechanisms through which B001 exert its effects have not been elucidated, B001 may induce a B-cell-directed cell-mediated immune response against CD20-expressing B cells and/or prevent CD20-medaited signaling. This induces tumor cell apoptosis and inhibits proliferation. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B cells during most stages of B-cell development and which is often overexpressed in B-cell malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:B 001
B001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search